Illustration: Tiffany Herring/Axios
Voltron Therapeutics, an oncology vaccine company, intends to go public in Q1 of 2026, a source familiar with the company's plans tells Axios Pro.
The big picture: The IPO market for biotechs appears to be reopening after a six-month-plus drought.
